Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Locksley Resources Adds 249 Additional Claims to Landholding of More than 40 sq km of Highly Prospective Critical Minerals Ground in California's Mojave Region
